IL1B and COVID-19: CAN-COVID (https://clinicaltrials.gov/ct2/show/NCT04362813) randomizes canikunimab (a monoclonal antibody that targets the IL-1β cytokine specifically) to patients with severe COVID-19, not requiring mechanical ventilation.